Discover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family.
© Umbricht et al. 2017
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
Winner of the journal’s Best Paper Award 2018
A preclinical investigation of 44Sc-PSMA-617 for its use as a diagnostic match to 177Lu-PSMA-617. Findings demonstrated greater similarities for the in vitro characteristics and in vivo kinetics of 44Sc-PSMA-617 to 177Lu-PSMA-617 than 68Ga-PSMA-617 and 68Ga-PSMA-11.
Congratulations to the authors: Christoph A. Umbricht, Martina Benešová, Raffaella M. Schmid, Andreas Türler, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller!
The award was presented at the EANM Congress 2018.
Articles
-
-
Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy
-
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
-
Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study
-
Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers
-
Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare
-
Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT
-
Post-radioembolization yttrium-90 PET/CT - part 1: diagnostic reporting
-
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
-
Measurement of metabolic tumor volume: static versus dynamic FDG scans
Aims and scope
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
EJNMMI Journal Family
EJNMMI Research aims to be a platform of lively scientific exchange on new findings in basic, translational and clinical research in nuclear medicine and related matters. It addresses research in biology and medicine together with radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation. The open access model speeds up the publication process and therefore favours rapid communication of new scientific results, even if still preliminary. Manuscripts are accepted for publication only after thorough peer review.
EJNMMI Research has been launched by Springer as a companion journal to the EJNMMI and not as a competitor. It offers space to authors whose manuscripts, despite high quality, cannot be accommodated by the EJNMMI. Consequently, authors of original manuscripts rejected by the EJNMMI are encouraged to submit their work to EJNMMI Research.
The journal also offers the possibility to publish reviews, short communications and selected case reports. Educational papers set out to improve and expand our understanding and knowledge in active research domains. Editorials and letters complete the exchange of views and ideas. We also welcome submission of well-designed studies that did not confirm the initial hypothesis, as we are convinced that they contribute to the advancement of science and should, therefore, be made available to the scientific community.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
Advertisement
Follow
- ISSN: 2191-219X (electronic)
Affiliated with
Annual Journal Metrics
-
Speed
36 days to first decision for reviewed manuscripts only
33 days to first decision for all manuscripts
77 days from submission to acceptance
17 days from acceptance to publicationCitation Impact
3.000 - 2-year Impact Factor
2.680 - 5-year Impact Factor
0.985 - Source Normalized Impact per Paper (SNIP)
1.067 - SCImago Journal Rank (SJR)Usage
188,554 Downloads
116 Altmetric Mentions
EJNMMI Journals
___________________________
___________________________
___________________________
___________________________
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Advertisement
